Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia
- PMID: 34790902
- PMCID: PMC8594913
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia
Abstract
DNA methylation, a key epigenetic driver of transcriptional silencing, is universally dysregulated in cancer. Reversal of DNA methylation by hypomethylating agents, such as the cytidine analogs decitabine or azacytidine, has demonstrated clinical benefit in hematologic malignancies. These nucleoside analogs are incorporated into replicating DNA where they inhibit DNA cytosine methyltransferases DNMT1, DNMT3A and DNMT3B through irreversible covalent interactions. These agents induce notable toxicity to normal blood cells thus limiting their clinical doses. Herein we report the discovery of GSK3685032, a potent first-in-class DNMT1-selective inhibitor that was shown via crystallographic studies to compete with the active-site loop of DNMT1 for penetration into hemi-methylated DNA between two CpG base pairs. GSK3685032 induces robust loss of DNA methylation, transcriptional activation and cancer cell growth inhibition in vitro. Due to improved in vivo tolerability compared with decitabine, GSK3685032 yields superior tumor regression and survival mouse models of acute myeloid leukemia.
Conflict of interest statement
Competing interests M.B.P., K.K., W.A.K., C.S., K.W., J.B., M.S., A.G., C.F.M., N.C., A.P.G., T.W., L.R., D.T.F., C.Z., J.L.H., M.Muliaditan, M.Mebrahtu, J.P.J., D.E.M., H.C.E., A.N.T., T.H., S.M., S.W.F., A. Rutkowska, M.L., S.P.R., M.B., A.J.J., E.M., P.G., M.P., A.B.B., H.P.M., A.G.G., R.K.P., C.C., D.H., B.W.K., J.I.L., R.G.K. and M.T.M. are/were employees and/or shareholders of GlaxoSmithKline (GSK). The remaining authors declare no competing interests.
Figures
![Extended Data Fig. 1 |](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8594913/bin/nihms-1750488-f0009.gif)
![Extended Data Fig. 2 |](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8594913/bin/nihms-1750488-f0010.gif)
![Extended Data Fig. 3 |](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8594913/bin/nihms-1750488-f0011.gif)
![Extended Data Fig. 4 |](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8594913/bin/nihms-1750488-f0012.gif)
![Extended Data Fig. 5 |](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8594913/bin/nihms-1750488-f0013.gif)
![Extended Data Fig. 6 |](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8594913/bin/nihms-1750488-f0014.gif)
![Extended Data Fig. 7 |](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8594913/bin/nihms-1750488-f0015.gif)
![Extended Data Fig. 8 |](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8594913/bin/nihms-1750488-f0016.gif)
![Fig. 1 |](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8594913/bin/nihms-1750488-f0001.gif)
![Fig. 2 |](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8594913/bin/nihms-1750488-f0002.gif)
![Fig. 3 |](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8594913/bin/nihms-1750488-f0003.gif)
![Fig. 4 |](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8594913/bin/nihms-1750488-f0004.gif)
![Fig. 5 |](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8594913/bin/nihms-1750488-f0005.gif)
![Fig. 6 |](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8594913/bin/nihms-1750488-f0006.gif)
![Fig. 7 |](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8594913/bin/nihms-1750488-f0007.gif)
![Fig. 8 |](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8594913/bin/nihms-1750488-f0008.gif)
Comment in
-
The next generation of DNMT inhibitors.Nat Cancer. 2021 Oct;2(10):1000-1001. doi: 10.1038/s43018-021-00271-z. Nat Cancer. 2021. PMID: 35121882 No abstract available.
Similar articles
-
Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia.Sci Rep. 2020 Jun 25;10(1):10325. doi: 10.1038/s41598-020-67170-8. Sci Rep. 2020. PMID: 32587297 Free PMC article.
-
Role of DNA methyltransferases in regulation of human ribosomal RNA gene transcription.J Biol Chem. 2006 Aug 4;281(31):22062-22072a. doi: 10.1074/jbc.M601155200. Epub 2006 May 30. J Biol Chem. 2006. Retraction in: J Biol Chem. 2018 Mar 9;293(10):3591. doi: 10.1074/jbc.W118.002433. PMID: 16735507 Free PMC article. Retracted.
-
A pharmacodynamic assay to monitor treatment with the hypomethylating cytosine analogs, decitabine and azacitidine.Methods Cell Biol. 2024;186:131-150. doi: 10.1016/bs.mcb.2024.02.016. Epub 2024 Mar 21. Methods Cell Biol. 2024. PMID: 38705597
-
DNA methyltransferases as targets for cancer therapy.Drugs Today (Barc). 2007 Jun;43(6):395-422. doi: 10.1358/dot.2007.43.6.1062666. Drugs Today (Barc). 2007. PMID: 17612710 Review.
-
Digging deep into "dirty" drugs - modulation of the methylation machinery.Drug Metab Rev. 2015 May;47(2):252-79. doi: 10.3109/03602532.2014.995379. Epub 2015 Jan 8. Drug Metab Rev. 2015. PMID: 25566693 Free PMC article. Review.
Cited by
-
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.Signal Transduct Target Ther. 2024 May 22;9(1):126. doi: 10.1038/s41392-024-01826-z. Signal Transduct Target Ther. 2024. PMID: 38773064 Free PMC article. Review.
-
Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal Transduct Target Ther. 2024 May 20;9(1):132. doi: 10.1038/s41392-024-01823-2. Signal Transduct Target Ther. 2024. PMID: 38763973 Free PMC article. Review.
-
DNMT1-targeting remodeling global DNA hypomethylation for enhanced tumor suppression and circumvented toxicity in oral squamous cell carcinoma.Mol Cancer. 2024 May 16;23(1):104. doi: 10.1186/s12943-024-01993-1. Mol Cancer. 2024. PMID: 38755637 Free PMC article.
-
Fragment-based discovery of new potential DNMT1 inhibitors integrating multiple pharmacophore modeling, 3D-QSAR, virtual screening, molecular docking, ADME, and molecular dynamics simulation approaches.Mol Divers. 2024 Apr 18. doi: 10.1007/s11030-024-10837-5. Online ahead of print. Mol Divers. 2024. PMID: 38637479
-
Non-canonical functions of UHRF1 maintain DNA methylation homeostasis in cancer cells.Nat Commun. 2024 Apr 5;15(1):2960. doi: 10.1038/s41467-024-47314-4. Nat Commun. 2024. PMID: 38580649 Free PMC article.
References
-
- Okano M, Bell DW, Haber DA & Li E DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99, 247–257 (1999). - PubMed
-
- Pradhan S, Bacolla A, Wells RD & Roberts RJ Recombinant human DNA (cytosine-5) methyltransferase. I. Expression, purification, and comparison of de novo and maintenance methylation. J. Biol. Chem 274, 33002–33010 (1999). - PubMed
-
- Bird A DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6–21 (2002). - PubMed
-
- Jones PA & Laird PW Cancer epigenetics comes of age. Nat. Genet 21, 163–167 (1999). - PubMed
-
- Baylin SB & Herman JG DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16, 168–174 (2000). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical